Delving into the Latest Updates on Hangzhou Cheetah Cell Therapeutics Co., Ltd with Synapse

Overview

Tags

Neoplasms

Urogenital Diseases

Digestive System Disorders

CAR-NK

Cell therapy

CAR-T

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	5
Hemic and Lymphatic Diseases	2
Endocrinology and Metabolic Disease	2
Immune System Diseases	2

Top 5 Drug Type	Count

Cell therapy	2
CAR-NK	2
CAR-T	1

Top 5 Target	Count

NKG2D(NKG2-D type II integral membrane protein)	1
PDL1(Programmed death-ligand 1)	1
BCMA(B-cell maturation protein)	1

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 17 Jun 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

3

Other

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

N03 ( BCMA )	Refractory Multiple Myeloma More	Clinical
T-01(Hangzhou Cheetah Cell Therapeutics) ( NKG2D )	Platinum-Resistant Ovarian Carcinoma More	Clinical
N02	Acute Lymphoblastic Leukemia More	Preclinical
Dual CAR-T cells(Cheetah Cell Therapeutics) ( PDL1 )	Colorectal Cancer More	Preclinical
N-04	Stomach Cancer More	Preclinical